MDGL

533.88

2.38% -13.01

Handel nachbörslich: 542.99 9.11 +1.71%

Madrigal Pharmaceuticals Inc (MDGL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MDGL? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$546.89

Offen:

$538.36

24-Stunden-Volumen:

293.92K

Relative Volume:

0.80

Marktkapitalisierung:

$12.25B

Einnahmen:

$958.40M

Nettoeinkommen (Verlust:

$-288.28M

KGV:

-41.50

EPS:

-12.8641

Netto-Cashflow:

$-193.02M

1W Leistung:

+5.65%

1M Leistung:

+23.35%

6M Leistung:

+20.70%

1J Leistung:

+69.81%

1-Tages-Spanne:

$530.41

$547.18

1-Wochen-Bereich:

$510.40

$547.98

52-Wochen-Spanne:

$265.00

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Firmenname

Madrigal Pharmaceuticals Inc

Sektor

Healthcare (1116)

Branche

Biotechnology (624)

Telefon

404-380-9263

Adresse

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Mitarbeiter

915

Twitter

@MadrigalPharma

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MDGL Madrigal Pharmaceuticals Inc	533.88	12.55B	958.40M	-288.28M	-193.02M	-12.86
VRTX Vertex Pharmaceuticals Inc	434.30	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.04	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.25	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.34	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.81	35.01B	606.42M	-1.28B	-997.58M	-6.403

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Eingeleitet	Barclays	Overweight
2026-01-06	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-11-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-11-03	Hochstufung	BofA Securities	Underperform → Neutral
2025-10-15	Eingeleitet	Truist	Buy
2025-09-04	Fortgesetzt	H.C. Wainwright	Buy
2025-02-28	Hochstufung	B. Riley Securities	Neutral → Buy
2025-02-27	Bestätigt	H.C. Wainwright	Buy
2024-06-28	Eingeleitet	Cantor Fitzgerald	Neutral
2024-06-11	Eingeleitet	Wolfe Research	Outperform
2024-04-22	Eingeleitet	BofA Securities	Underperform
2024-03-15	Hochstufung	B. Riley Securities	Sell → Neutral
2024-03-06	Eingeleitet	Citigroup	Buy
2024-02-26	Herabstufung	B. Riley Securities	Neutral → Sell
2022-12-20	Bestätigt	Oppenheimer	Outperform
2022-12-19	Bestätigt	H.C. Wainwright	Buy
2022-12-19	Bestätigt	Piper Sandler	Overweight
2022-12-19	Hochstufung	Raymond James	Underperform → Mkt Perform
2022-07-08	Herabstufung	B. Riley Securities	Buy → Neutral
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Fortgesetzt	Goldman	Buy
2020-11-24	Fortgesetzt	Evercore ISI	Outperform
2020-11-06	Bestätigt	H.C. Wainwright	Buy
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-06-05	Eingeleitet	BMO Capital Markets	Market Perform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-01-30	Eingeleitet	Canaccord Genuity	Buy
2020-01-09	Hochstufung	UBS	Neutral → Buy
2019-11-07	Bestätigt	H.C. Wainwright	Buy
2019-06-25	Eingeleitet	Stifel	Hold
2019-06-10	Hochstufung	B. Riley FBR	Neutral → Buy
2019-02-28	Bestätigt	H.C. Wainwright	Buy
2019-02-22	Eingeleitet	SVB Leerink	Outperform
2019-01-23	Eingeleitet	UBS	Neutral
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-12-12	Eingeleitet	B. Riley FBR	Neutral
2018-11-19	Herabstufung	Raymond James	Mkt Perform → Underperform
2018-11-16	Hochstufung	Evercore ISI	In-line → Outperform
2018-09-04	Eingeleitet	Citigroup	Buy
2018-08-06	Herabstufung	Goldman	Buy → Neutral
2018-06-28	Eingeleitet	Raymond James	Mkt Perform

Alle ansehen

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

07:29 AM

Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals (MDGL) - MSN

07:29 AM

05:11 AM

Capricorn Fund Managers Ltd Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

05:11 AM

03:32 AM

Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN

03:32 AM

Apr 04, 2026

MDGL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

Toth Financial Advisory Corp Makes New $1.17 Million Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Apr 04, 2026

Madrigal Pharmaceuticals Grants Equity Awards to New Employees Under 2025 Inducement Plan - MSN

Apr 04, 2026

Apr 03, 2026

MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN

Apr 03, 2026

What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy - MSN

Apr 03, 2026

Apr 02, 2026

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Apr 02, 2026

Apr 01, 2026

Madrigal Pharmaceuticals to Present at Morgan Stanley Global Health Care Conference - MSN

Apr 01, 2026

Madrigal grants equity awards to seven new employees - MSN

Apr 01, 2026

Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo

Apr 01, 2026

Mar 31, 2026

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step - Benzinga

Mar 31, 2026

Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra - Sahm

Mar 31, 2026

Madrigal Soars 5.87% on Strong Analyst Momentum and Institutional Shifts—Where to Now? - bitget.com

Mar 31, 2026

Hennion & Walsh Asset Management Inc. Sells 4,684 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 31, 2026

MDGL Technical Analysis | Trend, Signals & Chart Patterns | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill

Mar 31, 2026

Understanding Momentum Shifts in (MDGL) - Stock Traders Daily

Mar 31, 2026

Mar 30, 2026

Madrigal Pharmaceuticals grants equity awards to 20 new employees - MSN

Mar 30, 2026

Madrigal Pharmaceuticals (MDGL) surged on strong sales of its Rezdiffra drug - MSN

Mar 30, 2026

Assenagon Asset Management S.A. Acquires New Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 30, 2026

Mar 29, 2026

Madrigal Pharmaceuticals stock dips after team presence at Liver Connect Conference sees doubled attendance - Traders Union

Mar 29, 2026

Mar 27, 2026

Madrigal Reports $212.8M in Q2 Rezdiffra Sales, Expands Global Pipeline and Secures $500M Financing - MSN

Mar 27, 2026

Loss Report: What are analysts price targets for Madrigal Pharmaceuticals Inc2026 Bull vs Bear & Technical Pattern Based Signals - baoquankhu1.vn

Mar 27, 2026

MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits

Mar 27, 2026

Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug - Insider Monkey

Mar 27, 2026

Vanguard (MDGL) files amendment; reports 0 shares after Jan 12, 2026 realignment - Stock Titan

Mar 27, 2026

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains? - Yahoo Finance

Mar 27, 2026

Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? - Yahoo Finance

Mar 27, 2026

Mar 26, 2026

Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN

Mar 26, 2026

Rezdiffra Shows Promise as Madrigal’s Liver Drug Garners Positive Results - StocksToTrade

Mar 26, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 11.7% HigherShould You Buy? - marketbeat.com

Mar 26, 2026

Madrigal Surges 11.66%: A Volatile Breakout Defies Sector Stagnation as Bulls Test $572 - Bitget

Mar 26, 2026

Madrigal Grants Equity Awards to Seven New Employees - MyChesCo

Mar 26, 2026